▶ IPAMORELIN · SUBTOPIC · SAFETY PROFILE
IPAMORELIN Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of IPAMORELIN.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of IPAMORELIN. Severity, frequency, and attribution depend on the source publication.
- Mild injection-site reactions
- Transient hunger (mild)
- Rare water retention
- Rare mild flushing
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for IPAMORELIN.
- Concurrent rhGH not recommended
- Insulin / glucose-lowering agents (mild hyperglycemia possible)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for IPAMORELIN in the published record:
- Active malignancy
- Pituitary tumor
- Pregnancy/lactation (unstudied)
FDA REGULATORY STATUS
Not FDA-approved. Helsinn/Lilly Phase 2 postoperative ileus program discontinued. Research-use only.
WADA REGULATORY STATUS
Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).
SAFETY Q+A FROM LITERATURE
▶ Is ipamorelin FDA-approved?
No. The Helsinn/Lilly Phase 2 postoperative ileus program (Beck et al. 2014, PMID 25331030) was discontinued. No subsequent FDA approval.
▶ Is ipamorelin WADA-prohibited?
Yes. Ipamorelin is prohibited at all times under WADA Section S2 in the growth-hormone-secretagogue sub-category.
▶ What are the side effects of ipamorelin?
Mild injection-site reactions, transient hunger (mild ghrelin-receptor activation), rare water retention, rare mild flushing. Cleaner profile than older non-selective GHS like GHRP-6.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822. link
- Beck DE, Sweeney WB, McCarter MD, et al.. Safety and pharmacology of ipamorelin in healthy volunteers and postoperative ileus patients. J Gastrointest Surg 2014. PMID 25331030. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-25